Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2017: Volume 22/ Issue 16 Article 3
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 22, Issue 16, 20 April 2017
Research article
Fafangel, Cassini, Colzani, Klavs, Grgič Vitek, Učakar, Muehlen, Vudrag, and Kraigher: Estimating the annual burden of tick-borne encephalitis to inform vaccination policy, Slovenia, 2009 to 2013

+ Author affiliations


Citation style for this article: Fafangel M, Cassini A, Colzani E, Klavs I, Grgič Vitek M, Učakar V, Muehlen M, Vudrag M, Kraigher A. Estimating the annual burden of tick-borne encephalitis to inform vaccination policy, Slovenia, 2009 to 2013. Euro Surveill. 2017;22(16):pii=30509. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.16.30509

Received:11 July 2016; Accepted:09 September 2016


Introduction

Tick-borne encephalitis (TBE) is a vector-borne disease caused by the TBE virus [1]. It typically presents as a two-phased illness [2-4]. The first phase is associated with symptoms such as fever, fatigue, headache, myalgia and nausea. The second phase involves the nervous system with symptoms related to meningitis and/or encephalitis. Life-long sequelae can have an important impact on the quality of life of those affected [5]. TBE cases notified in Europe have surged in the last three decades with an estimated increase of 193% [6-8].

In Slovenia, notification of TBE is mandatory and based on the European Union (EU) standardised case definition [9]. Only cases with central nervous system involvement (meningoencephalitic TBE) and laboratory confirmation are notified. Slovenia is one of the countries with the highest notified incidence in Europe, ranging from 8 to 15 per 100,000 in the period from 2009 to 2013, with cases occurring throughout the country [10]. Data for the past 20 years show a non-homogenous age distribution with higher incidence in older age groups (> 40 years) [10]. Preventive measures include the use of repellents, appropriate clothing and daily inspection of the skin to remove ticks [11]. The most effective method of preventing TBE is vaccination [11-13]. Mandatory vaccination against TBE was introduced in Slovenia in 1986 for those at risk of occupational exposure, and in 1990 for students at risk of exposure during curricular training, while the rest of the population needs to pay for the vaccination themselves. TBE vaccination coverage in Slovenia remains low: by 2007, the proportion of the general population reporting to ever have been vaccinated against TBE was 12.4% [14].

In a context where limited resources prevent universal TBE vaccination free of charge, data are needed to identify those groups most affected by the disease so that vaccination can be targeted in order to yield the greatest benefit on population health. Countries have used incidence data to guide vaccination strategies towards specific age groups and geographical areas [15-17]. Estimation of the TBE burden in the form of disability-adjusted life years (DALYs), a summary measure of population health, is better suited to express the overall and age group-specific impact of the disease in the population while taking into account the effects of acute illness and its sequelae on mortality and morbidity [18]. The objective of this study was to estimate the overall and age- and sex-specific annual burden of TBE in Slovenia in order to inform vaccination policy in a setting with limited resources.

Methods

Model

To estimate the burden of TBE we used the pathogen-based incidence approach developed by the European Centre for Disease Prevention and Control (ECDC) Burden of communicable diseases in Europe project (BCoDE) [18-20]. The burden was expressed in DALYs. DALYs have two components: years of life lost due to premature death (YLL) and healthy years of life lost due to disability (YLD) [21].

We used a disease model (outcome tree) based on the current knowledge of the disease progression pathway, linking all health outcomes related to TBE with the initial infection. Starting with the infection a case moved through the outcome tree transitioning into different health outcomes according to different conditional transition probabilities (i.e. probability of occurrence of each health outcome), exiting the tree with a resolved infection, with a life-long disability or with a fatal outcome. In order to measure YLL, life expectancy was based on the standard reference life table developed within the Global Burden of Disease 2010 project [22]. To measure YLD, each health outcome was characterised by a disease duration and a disability weight. Disability weights quantify health losses to reflect the disability experienced by someone living with a health issue. Based on the severity of the disease, they range from 0 (full health) to 1 (death). The disability weights were generated for BCoDE and the Global Burden of Disease study (GBD) 2013 through elicitation methods [23,24]. The outcome tree for TBE used in our model (Figure 1) was based on a thorough review of published studies and on the opinion of ECDC experts [25]. All parameters included in the outcome tree, conditional transition probabilities, durations and disability weights were based on published studies and entailed a certain level of uncertainty. The uncertainty was modelled by incorporating ranges using either uniform or Pert distributions [26] and quantified by performing Monte Carlo simulations with 10,000 iterations to obtain 95% uncertainty intervals (UI). In order to assess age groups of interest for vaccination strategies, we compared the median DALYs and their 95% UIs.

Figure 1

Outcome tree for tick-borne encephalitis virus infection

/images/dynamic/articles/22778/16-00469-f1

DW: disability weight; R: resolution of infection; TBE: tick-borne encephalitis.

Input data

The ECDC BCoDE toolkit was used for DALY estimation [25]. Input data for the model were the mean annual numbers of meningoencephalitic TBE cases notified to the Slovenian national surveillance system for communicable diseases from 2009 to 2013. They were stratified by 5-year age groups and by sex. For those calculations where a population estimate was required, we used the 2011 population data for Slovenia obtained from Eurostat [27]. The main type of input data for TBE in the BCoDE toolkit was the number of symptomatic infections (first phase of the disease); to obtain this, surveillance data were multiplied by the appropriate transitional probabilities as specified by the TBE outcome tree. No time discounting was applied, thus future and present disabilities were weighted equally.

Results

From 2009 to 2013, a total of 1,190 cases (58% males) of TBE in their meningoencephalitic phase were notified in Slovenia, with a mean of 238 cases/year. The median age at diagnosis was 51 years (range: 1–86 years). The mean annual incidence of meningoencephalitic TBE was 11.6 per 100,000 population (9.6/100,000 for females and 13.6/100,000 for males). Incidence was higher in older individuals (50–74 years: 18.5/100,000) than in children (5–14 years: 10.2/100,000). Data by 5-year age groups and by sex are presented in Figure 2.

Figure 2

Mean annual incidence per100,000 of tick-borne encephalitis, by age and sex, Slovenia, 2009–2013 (n = 1,190)

/images/dynamic/articles/22778/16-00469-f2

The estimated DALYs per year were 224.52 (95% UI: 210.14-238.84), corresponding to 10.95 DALYs per 100,000 per year (95% UI: 10.25-11.65). Each case of TBE accounted for an average of 0.23 DALYs (95% UI: 0.22–0.24) In the Table, DALYs and their components (YLL and YLD) are presented for all health outcomes related to TBE. YLDs per year accounted for 67% of the total disease burden. Late sequelae, following the meningoencephalitic phase of the disease, contributed to 63% of the DALYs per year.

Table

Tick-borne encephalitis annual burden estimates, Slovenia, 2009–2013

     DALYs/year     
(95% UI)
DALYs/100,000
(95% UI)
     YLL/year     
(95% UI)
       YLD/year       
(95% UI)
Symptomatic infection 0.67
(0.61–0.73)
0.03
(0.03–0.04)
0 0.67
(0.61–0.73)
Meningoencephalitic phase 81.94
(76.77–87.15)
4.00
(3.74–4.25)
74.88
(70.14–79.56)
7.06
(5.92–8.36)
Post-encephalitic TBE syndrome 21.36
(19.87–22.91)
1.04
(0.97–1.12)
0 21.36
(19.87–22.91)
Paralysis 0.20
(0.18–0.21)
< 0.001 0 0.20
(0.18–0.21)
Residual paresis 34.32
(31.98–36.73)
1.67
(1.56–1.79)
0 34.32
(31.98–36.73)
Chronic post-encephalitic TBE syndrome 86.04
(79.87–92.31)
4.20
(3.90–4.50)
0 86.04
(79.87–92.31)
Total 224.52
(210.14–238.84)
10.95
(10.25–11.65)
74.88
(70.14–79.56)
149.64
(139.67159.75)

DALYs: disability-adjusted life years; TBE: tick-borne encephalitis; UI: uncertainty interval; YLD: healthy years of life lost due to disability; YLL: years of life lost.

The group of 50–54-year-old women and the group of 25–29-year-old men had the highest point estimates of DALYs per year with 10.56 (95% UI: 7.34–14.03) and 13.02 (95% UI: 9.25–17.49) DALYs per year respectively. When looking at both sexes together, the 50–54 and 55–59-year-olds accounted for the highest number of DALYs, 21.08 (95% UI: 14.91–28.40) and 20.48 (95% UI: 14.48–27.70), respectively.

In terms of DALYs per 100,000 stratum-specific population, the highest burden point estimate was among the 5–9-year-olds: 19.29 DALYs per 100,000 stratum-specific population per year (95% UI: 15.41–23.90) with 16.62 DALYs (95% UI: 11.48–22.51) and 21.69 DALYs per 100,000 per year (95% UI: 15.12–29.28) for girls and boys, respectively. Data by 5-year age groups and by sex are presented in Figure 3.

Figure 3

Estimated mean annual disability-adjusted life years per 100,000 stratum-specific population due to tick-borne encephalitis, by age and sex, Slovenia, 2009–2013

/images/dynamic/articles/22778/16-00469-f3

DALYs: disability-adjusted life years.

The whiskers represent 95% uncertainty intervals.

The group of 50–74-year-olds had a lower TBE burden estimate of 11.58 (95% UI: 10.25–12.91) DALYs per 100,000 stratum-specific population per year in comparison to the 5–14-year-olds with a burden of 17.31 (95% UI: 14.58–20.08) DALYs per 100,000 stratum-specific population per year (Figure 4).

Figure 4

Estimated mean annual incidence per 100,000 and mean annual disability-adjusted life years per 100,000 stratum-specific population due to tick-borne encephalitis, by age group, Slovenia, 2009–2013

/images/dynamic/articles/22778/16-00469-f4

DALYs: disability-adjusted life years.

The whiskers represent 95% uncertainty intervals.

Discussion

In this paper we present the overall and the age- and sex-specific annual burden of TBE in Slovenia expressed in DALYs. The use of DALYs integrates mortality and morbidity from TBE in a single composite health metric, giving a comprehensive estimate of the impact of this disease on population health.

An analysis of notified TBE cases in the 5-year period from 2009 to 2013 confirms Slovenia as one of the countries, together with the Baltic states and the Russian Federation, where reported incidence per 100,000 is the highest in Europe [11,28]. With an estimate of 10.95 DALYs per 100,000 per year (95% UI: 10.25-11.65), TBE has an important impact on the health of the Slovenian population. In accordance with input incidence data, we found consistently higher burden point estimates in male persons across all ages. According to the BCoDE 2009–13 study, the estimated burden of TBE in Slovenia was nine times higher than the corresponding estimated burden of TBE measured in DALYs per 100,000 population per year for the EU and European Economic Area (EEA) for the same time period [29]. Moreover, the impact of TBE on the Slovenian population is comparable to that of healthcare-associated neonatal sepsis (16.8 DALYs/100,000) according to a recent study on healthcare-associated infection in the EU/EEA [30].

Looking at incidence data alone, older age groups (50–74-year-olds) appeared most affected by TBE in Slovenia. However, the use of DALYs identified children (5–14-year-olds) as the group with a higher burden. This difference in impact of TBE would not have been detected, if we had limited our assessment to incidence data, ignoring the combined effects of morbidity, short- and long-term sequelae and mortality. Other countries with a similar TBE incidence profile as Slovenia could profit from this approach to identify groups with important burden, particularly when informing decision makers about the allocation of limited resources for targeted public health interventions (i.e. vaccination).

Vaccination is regarded as the most effective preventive measure for TBE [11]. Studies have shown a 96–99% field effectiveness in persons receiving three doses following the recommended schedule [12,13]. In neighbouring Austria, an estimated 88% of the general population are vaccinated with at least one dose, while 58% are vaccinated regularly following the advised schedule [13]. Austria has managed to reduce the number of TBE cases by 90% by increasing its vaccination rate from 6% in 1980 to its current level [13]. Despite the fact that vaccination has been recommended in Slovenia for decades, only 12% of the population was vaccinated with at least one dose by 2007 and only 7.3% get vaccinated regularly following the advised schedule [31].

TBE vaccination remains a self-paid expense for the majority of the population. The costs are covered by the mandatory insurance system or by the employer only in case of occupational exposure or exposure during education or training. Data from 2007 show that only 4.6% of the population paid themselves for TBE vaccination [14]. A recent study from Šmit et al., estimating DALYs of TBE in Slovenia using the GBD project methodological approach, supports the need for a public health strategy aimed at increasing the national vaccination coverage [32]. Multiple factors influencing the decision to get vaccinated against TBE (knowledge, trust, accessibility, cost) should be considered when planning strategies aimed at increasing vaccination coverage [33]. Projections, however, show that the impact of a vaccine subsidy, making the vaccine free of charge, could alone increase coverage by 45%, and even more in low-income households [34].

Increasing TBE vaccination coverage should be considered as an option for intervention to reduce the impact of TBE [10,32]. In the presence of limited resources, the implementation of such a measure could be difficult in the short term. Our results suggest that effective prevention of TBE in children would have the highest impact in terms of DALYs of TBE averted. This novel insight in the distribution of TBE burden should be considered when prioritising access to TBE vaccination and could improve previous recommendations originating from incidence data alone, where the focus was mainly on older age groups [10].

Prioritising vaccination in children could be easier thanks to the well-functioning Slovenian national childhood immunisation programme. It is also important to take into account the need for booster doses of the TBE vaccine. In the age groups of interest, a three-dose primary vaccination schedule with a first booster dose after 3 years and further boosters every 5 years is recommended to maintain seropositivity [35]. A recent study showed that a schedule that includes the first booster dose yields a high and long-lasting (> 5 years) immune response, thus suggesting that subsequent TBE booster intervals could be extended beyond the current recommendation [36]. Considering the financial implications of lifelong booster doses (and the different schedules that apply at different ages), age-specific cost-effectiveness studies are needed to inform decisions on the extent to which TBE vaccine can be subsidised in order to achieve the highest level of immunopersistence and impact on TBE burden in a cost-effective manner.

We considered prioritising the most affected areas or regions as an alternative approach. Although some regions in Slovenia are more affected then others, TBE occurs throughout the country. Considering the epidemiological situation of TBE in Slovenia, the country`s relatively small area and population size, as well as the mobility of the population between regions, we consider this approach could be potentially misleading and lead to health inequalities. Other countries where restricted areas or regions are affected could consider a modelling approach stratified by region.

This study has certain limitations. The outcome tree describing the progression pathway of the disease assumes no differences in disease progression between different age groups. Lifelong sequelae make an important contribution to the overall burden, especially in the younger age groups. The disease in children is commonly regarded as mild, but evidence is increasing for the relevance of severe acute disease and long-term sequelae of TBE in children, as well as for the lack of knowledge around the matter [5,37-46]. The uncertainty around the disease progression, overall and for different age groups, can lead to an over- or underestimation of the burden overall and in different age groups. Future study of the disease progression of TBE in different age groups is needed and could improve the accuracy of the model. Another limitation of our study is that the data set used for input in the model was not corrected for underestimation (due to under-reporting and under-ascertainment) of the surveillance system [47]. At the moment of writing, data on underestimation of TBE notification were not available. However, taking into consideration the structure of the morbidity surveillance pyramid [47], we can assume that the notified data were still underestimating the true incidence of disease, thus leading to an underestimation of our burden estimates.

DALYs are a composite health metric highly dependent on the assumptions made; it is commonly used for ranking the relative burden of diseases within the same study, in cost-effectiveness analyses or evaluations of interventions (e.g. DALYs averted). The differences in absolute values between our results and the recent study from Šmit et al. [32] are probably due to differences in underlying assumptions and disease modelling approaches. Šmit et al. used data from a single year that had more cases than the 5-year annual average we used; they used an underestimation coefficient (4.5) for the number of cases of meningoencephalitic TBE, but we did not find enough evidence to make such assumptions; they modelled all neurological sequelae as lifelong. Moreover, Šmit et al. used higher transitional probabilities (in the age groups older than 15 years) and higher disability weights when modelling mild sequelae. Taking this into consideration, a direct comparison is not valid. Our focus on the distribution of the TBE burden across different age groups enabled us to suggest efficient options for vaccination.

Conclusion

We identified a higher burden of TBE among children aged 5–14 years than among adults aged 50–74 years despite a lower TBE incidence. Incidence data alone do not fully reflect the disease impact and should not be the only indicator to inform vaccination policy. In a limited resource setting where prioritisation of TBE vaccination strategies is required, vaccination programmes targeting children should be considered as possibly having a higher impact on disease burden. Our data could be used for future cost-effectiveness studies.


Conflict of interest

None declared.

Authors’ contributions

MF and AC were responsible for the conception and design of this study. MF drafted the first study protocol, and AC, EC, IK, MM contributed to further drafts. MF and MG collected and assembled the data. MF undertook the primary data analysis in collaboration with AC. All authors had an opportunity to contribute to the interpretation of the results. MF wrote the first draft of the manuscript, and all other authors contributed to further drafts.


References

  1. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication.Annu Rev Microbiol. 1990;44(1):649-88. DOI: 10.1146/annurev.mi.44.100190.003245 PMID: 2174669

  2. Gubler JD, Kuno G, Markoff L. Flaviviruses. In: Knipe DM, Howley PM, editors. Fields Virology. 5th ed. London, New York, Tokyo: Lippincott Williams and Wilkins; 2007. pp. 1043-1125.

  3. Kiffner C, Zucchini W, Schomaker P, Vor T, Hagedorn P, Niedrig M,  et al.  Determinants of tick-borne encephalitis in counties of southern Germany, 2001-2008. Int J Health Geogr. 2010;9(1):42. DOI: 10.1186/1476-072X-9-42 PMID: 20707897

  4. Gustafson R, Svenungsson B, Forsgren M, Gardulf A, Granström M. Two-year survey of the incidence of Lyme borreliosis and tick-borne encephalitis in a high-risk population in Sweden.Eur J Clin Microbiol Infect Dis. 1992;11(10):894-900. DOI: 10.1007/BF01962369 PMID: 1486884

  5. Haglund M, Günther G. Tick-borne encephalitis--pathogenesis, clinical course and long-term follow-up.Vaccine. 2003;21(Suppl 1):S11-8. DOI: 10.1016/S0264-410X(02)00811-3

  6. European Centre for Disease Prevention and Control. Epidemiological situation of tick-borne encephalitis in the European Union and European Free Trade Association countries. Stockholm: ECDC; 2012. Available from: http://ecdc.europa.eu/en/publications/Publications/TBE-in-EU-EFTA.pdf

  7. Suss J. Tick-borne encephalitis in Europe and beyond--the epidemiological situation as of 2007.Euro Surveill. 2008;13(26):18916.PMID: 18761916

  8. Süss J. Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview.Ticks Tick Borne Dis. 2011;2(1):2-15. DOI: 10.1016/j.ttbdis.2010.10.007 PMID: 21771531

  9. European Commision. Commission implementing decision of 8 August 2012 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. Off J Eur Union 2012;55(L 262):1–57. http://dx.doi.org/DOI: 10.3000/19770677.L_2012.262.eng

  10. Grgič-Vitek M, Klavs I. High burden of tick-borne encephalitis in Slovenia--challenge for vaccination policy.Vaccine. 2011;29(32):5178-83. DOI: 10.1016/j.vaccine.2011.05.033 PMID: 21620916

  11. Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol Rec. 2011;86(24):241-56.PMID: 21661276

  12. Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against tick-borne encephalitis.Vaccine. 2007;25(43):7559-67. DOI: 10.1016/j.vaccine.2007.08.024 PMID: 17869389

  13. Kunz C. TBE vaccination and the Austrian experience.Vaccine. 2003;21(Suppl 1):S50-5. DOI: 10.1016/S0264-410X(02)00813-7 PMID: 12628814

  14. Grgic-Vitek M, Klavs I. Low coverage and predictors of vaccination uptake against tick-borne encephalitis in Slovenia.Eur J Public Health. 2012;22(2):182-6. DOI: 10.1093/eurpub/ckr018 PMID: 21398380

  15. Košnik IG, Lah AK. A campaign to increase the vaccination rate in a highly endemic tick-borne encephalitis region of Slovenia.Vaccine. 2013;31(5):732-4. DOI: 10.1016/j.vaccine.2012.12.005 PMID: 23246549

  16. Rapola S. National immunization program in Finland.Int J Circumpolar Health. 2007;66(5):382-9. DOI: 10.3402/ijch.v66i5.18310 PMID: 18274204

  17. Lucenko I, Jansone I, Velicko I, Pujate E. Tickborne encephalitis in Latvia.Euro Surveill. 2004;8(26):2495.

  18. Mangen M-JJ, Plass D, Havelaar AH, Gibbons CL, Cassini A, Mühlberger N,  et al.  The pathogen- and incidence-based DALY approach: an appropriate [corrected] methodology for estimating the burden of infectious diseases. PLoS One. 2013;8(11):e79740. DOI: 10.1371/journal.pone.0079740 PMID: 24278167

  19. Kretzschmar M, Mangen M-JJ, Pinheiro P, Jahn B, Fèvre EM, Longhi S,  et al.  New methodology for estimating the burden of infectious diseases in Europe. PLoS Med. 2012;9(4):e1001205. DOI: 10.1371/journal.pmed.1001205 PMID: 22529750

  20. Colzani E, Cassini A, Lewandowski D, Mangen MJ, Plass D, McDonald SA,  et al.  A Software Tool for Estimation of Burden of Infectious Diseases in Europe Using Incidence-Based Disability Adjusted Life Years. PLoS One. 2017;12(1):e0170662. DOI: 10.1371/journal.pone.0170662 PMID: 28107447

  21. Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years.Bull World Health Organ. 1994;72(3):429-45.PMID: 8062401

  22. Murray CJL, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C,  et al.  GBD 2010: design, definitions, and metrics. Lancet. 2012;380(9859):2063-6. DOI: 10.1016/S0140-6736(12)61899-6 PMID: 23245602

  23. Haagsma JA, Maertens de Noordhout C, Polinder S, Vos T, Havelaar AH, Cassini A,  et al.  Assessing disability weights based on the responses of 30,660 people from four European countries. Popul Health Metr. 2015;13(1):10. DOI: 10.1186/s12963-015-0042-4 PMID: 26778920

  24. Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH,  et al.  Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3(11):e712-23. DOI: 10.1016/S2214-109X(15)00069-8

  25. European Centre for Disease Prevention and Control (ECDC). Burden of communicable diseases in Europe Toolkit. Application to calculate DALYs. Version 1.1. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/healthtopics/burden_of_communicable_diseases/Pages/Tool.aspx

  26. Vose D. Risk Analysis: A Quantitative Guide. 2nd ed. Chichester: John Wiley and Sons, Ltd; 2001.

  27. Eurostat database. Brussels: European Commission. [Accessed 1 Sep 2015]. Available from: http://ec.europa.eu/eurostat/data/database

  28. Stefanoff P, Polkowska A, Giambi C, Levy-Bruhl D, O’Flanagan D, Dematte L,  et al.  Reliable surveillance of tick-borne encephalitis in European countries is necessary to improve the quality of vaccine recommendations. Vaccine. 2011;29(6):1283-8. DOI: 10.1016/j.vaccine.2010.11.077 PMID: 21145914

  29. Colzani E. Results from the 2015 Burden of Communicable Diseases in Europe (BCoDE) study. Milan: European Public Health Conference, 14-18 October; 2015.

  30. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Ducomble T,  et al.  Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study. PLoS Med. 2016;13(10):e1002150. DOI: 10.1371/journal.pone.0144988 PMID: 26672751

  31. National Institute of Public Health (NIJZ). Epidemiološko spremljanje nalezljivih bolezni v sloveniji v letu 2013. [Epidemiological surveillance of communicable disease in Slovenia in 2013]. Ljubljana: NIJZ; 2014. Slovenian. Available from: http://www.nijz.si/sites/www.nijz.si/files/publikacije-datoteke/epidemilosko_spremljanje_nalezljivih_bolezni_2013.pdf

  32. Šmit R, Postma MJ. The Burden of Tick-Borne Encephalitis in Disability-Adjusted Life Years (DALYs) for Slovenia.PLoS One. 2015;10(12):e0144988. DOI: 10.1371/journal.pone.0144988 PMID: 26672751

  33. Askling HH, Insulander M, Hergens M-P, Leval A. Tick borne encephalitis (TBE)-vaccination coverage and analysis of variables associated with vaccination, Sweden.Vaccine. 2015;33(38):4962-8. DOI: 10.1016/j.vaccine.2015.07.030 PMID: 26207593

  34. Slunge D. The Willingness to Pay for Vaccination against Tick-Borne Encephalitis and Implications for Public Health Policy: Evidence from Sweden.PLoS One. 2015;10(12):e0143875. DOI: 10.1371/journal.pone.0143875 PMID: 26641491

  35. Loew-Baselli A, Poellabauer EM, Pavlova BG, Fritsch S, Firth C, Petermann R,  et al.  Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine. 2011;29(43):7307-19. DOI: 10.1016/j.vaccine.2011.07.089 PMID: 21843576

  36. Beran J, Xie F, Zent O. Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety.Vaccine. 2014;32(34):4275-80. DOI: 10.1016/j.vaccine.2014.06.028 PMID: 24950352

  37. Cizman M, Rakar R, Zakotnik B, Pokorn M, Arnez M. Severe forms of tick-borne encephalitis in children.Wien Klin Wochenschr. 1999;111(12):484-7.PMID: 10420507

  38. Fröding I, Hjertqvist M. [Severe TBE with sequelae can also affect young children. Vaccination advice to children should be individualized, degree of exposure essential]. Lakartidningen. 2013;110(42):1861-4.PMID: 24294655

  39. Sundin M, Hansson MEA, Engman M-L, Orvell C, Lindquist L, Wide K,  et al.  Pediatric tick-borne infections of the central nervous system in an endemic region of Sweden: a prospective evaluation of clinical manifestations. Eur J Pediatr. 2012;171(2):347-52. DOI: 10.1007/s00431-011-1542-2 PMID: 21842178

  40. Schmolck H, Maritz E, Kletzin I, Korinthenberg R. Neurologic, neuropsychologic, and electroencephalographic findings after European tick-borne encephalitis in children.J Child Neurol. 2005;20(6):500-8. DOI: 10.1177/088307380502000606 PMID: 15996399

  41. Engman M-L, Lindström K, Sallamba M, Hertz C, Sundberg B, Hansson MEA,  et al.  One-year follow-up of tick-borne central nervous system infections in childhood. Pediatr Infect Dis J. 2012;31(6):570-4. DOI: 10.1097/INF.0b013e31824f23c0 PMID: 22333696

  42. Hansson MEA, Orvell C, Engman M-L, Wide K, Lindquist L, Lidefelt K-J,  et al.  Tick-borne encephalitis in childhood: rare or missed? Pediatr Infect Dis J. 2011;30(4):355-7. DOI: 10.1097/INF.0b013e3181fe3b5a PMID: 21412206

  43. Lidefelt K-J, Lindquist L, Engman M-L, Sundin M. [TBE (tick-borne encephalitis) in childhood--is it dangerous?]. Lakartidningen. 2013;110(9-10):452-3.PMID: 23540023

  44. Leistner C, Dahlem P. Tick-borne meningoencephalitis in a 4.5-month-old infant.Klin Padiatr. 2011;223(4):242-3. DOI: 10.1055/s-0030-1263193 PMID: 20814849

  45. Fowler Å, Forsman L, Eriksson M, Wickström R. Tick-borne encephalitis carries a high risk of incomplete recovery in children.J Pediatr. 2013;163(2):555-60. DOI: 10.1016/j.jpeds.2013.01.037 PMID: 23452585

  46. Fritsch P, Gruber-Sedlmayr U, Pansi H, Zöhrer B, Mutz I, Spork D,  et al.  Tick-borne encephalitis in Styrian children from 1981 to 2005: a retrospective study and a review of the literature. Acta Paediatr. 2008;97(5):535-8. DOI: 10.1111/j.1651-2227.2008.00763.x PMID: 18394095

  47. Gibbons CL, Mangen M-JJ, Plass D, Havelaar AH, Brooke RJ, Kramarz P,  et al.  Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. BMC Public Health. 2014;14(1):147. DOI: 10.1186/1471-2458-14-147 PMID: 24517715



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.